Clinical trial
A Multi-Center, Double-Blind Trial to Evaluate the Safety and Efficacy of Concurrent Retrovir (Zidovudine) and Zovirax (Acyclovir) Therapy in Patients With Early Symptomatic Human Immunodeficiency Virus (HIV) Infection
NCT00002290 is registered in ClinicalTrials.gov with Glaxo Wellcome as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-Center, Double-Blind Trial to Evaluate the Safety and Efficacy of Concurrent Retrovir (Zidovudine) and Zovirax (Acyclovir) Therapy in Patients With Early Symptomatic Human Immunodeficiency Virus (HIV) Infection
- Lead sponsor
- Glaxo Wellcome
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- Not reported
- Completion date
- Not reported
- Enrollment
- Not reported
- Sites
- 14
Conditions
As the registry lists them; a condition with its own page is linked.